Whole Egg

Phase 3Small molecule

PPenn State University

Whole Egg is one of 2 small molecule programs targeting Cardiovascular Diseases. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseasesActive, not recruiting

Cardiovascular DiseasesPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Cardiovascular Diseases

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

1 2

Whole Egg

PPenn State University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Cardiovascular Diseases

NCT06120400

Clinical

Trials by Indication[1]

Cardiovascular Diseases1 trial

Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs: a Controlled-feeding Study

Active, not recruiting·PPenn State University·Phase 3·NCT06120400·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Whole Egg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Whole Egg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Whole Egg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Penn State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPenn State University

Whole Egg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cardiovascular Diseases1 trial

References

Drug Info

Quick Facts

Related News